| Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy UH Gandhi, RF Cornell, A Lakshman, ZJ Gahvari, E McGehee, ... Leukemia 33 (9), 2266-2275, 2019 | 586 | 2019 |
| Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria A Lakshman, SV Rajkumar, FK Buadi, M Binder, MA Gertz, MQ Lacy, ... Blood cancer journal 8 (6), 59, 2018 | 267 | 2018 |
| Natural history of t (11; 14) multiple myeloma A Lakshman, M Alhaj Moustafa, SV Rajkumar, A Dispenzieri, MA Gertz, ... Leukemia 32 (1), 131-138, 2018 | 83 | 2018 |
| Prevalence and risk factors of hypertension among male occupational bus drivers in North Kerala, South India: a cross‐sectional study A Lakshman, N Manikath, A Rahim, VP Anilakumari International Scholarly Research Notices 2014 (1), 318532, 2014 | 75 | 2014 |
| Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma A Lakshman, PP Singh, SV Rajkumar, A Dispenzieri, MQ Lacy, MA Gertz, ... American journal of hematology 93 (2), 179-186, 2018 | 64 | 2018 |
| Impact of acquired del (17p) in multiple myeloma A Lakshman, U Painuly, SV Rajkumar, RP Ketterling, P Kapoor, ... Blood advances 3 (13), 1930-1938, 2019 | 58 | 2019 |
| Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials A Lakshman, JP Abeykoon, SK Kumar, SV Rajkumar, D Dingli, FK Buadi, ... American journal of hematology 92 (11), 1146-1155, 2017 | 51 | 2017 |
| Natural history of multiple myeloma with de novo del (17p) A Lakshman, U Painuly, SV Rajkumar, RP Ketterling, P Kapoor, ... Blood cancer journal 9 (3), 32, 2019 | 45 | 2019 |
| Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance A Lakshman, S Paul, SV Rajkumar, RP Ketterling, PT Greipp, ... Leukemia 32 (8), 1811-1815, 2018 | 44 | 2018 |
| Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: an update A Lakshman, SK Kumar American journal of hematology 97 (1), 99-118, 2022 | 40 | 2022 |
| Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH R Cornell, P Hari, S Tang, N Biran, N Callander, A Chari, S Chhabra, ... American journal of hematology 96 (1), E5-E8, 2021 | 30 | 2021 |
| Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma MA Aljama, MH Sidiqi, A Lakshman, A Dispenzieri, D Jevremovic, ... Blood Advances 2 (22), 3149-3154, 2018 | 30 | 2018 |
| Antisynthetase syndrome: an under-recognized cause of interstitial lung disease VN Maturu, A Lakshman, A Bal, V Dhir, A Sharma, M Garg, B Saikia, ... Lung India 33 (1), 20-26, 2016 | 30 | 2016 |
| Evaluation of bortezomib-induced neuropathy using total neuropathy score (reduced and clinical versions) and NCI CTCAE v4. 0 in newly diagnosed patients with multiple myeloma … A Lakshman, M Modi, G Prakash, P Malhotra, A Khadwal, S Jain, ... Clinical Lymphoma Myeloma and Leukemia 17 (8), 513-519. e1, 2017 | 25 | 2017 |
| Elevated cardiac biomarkers and echocardiographic left ventricular dysfunction at admission in patients with dengue fever: report from a tertiary care center in Northwest India A Lakshman, P Balasubramanian, RV Nampoothiri, R Vijayvergiya, ... Tropical Doctor 48 (4), 261-265, 2018 | 17 | 2018 |
| Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 8 (6): 59 A Lakshman, SV Rajkumar, FK Buadi, M Binder, MA Gertz, MQ Lacy, ... | 17 | 2018 |
| Overall survival of triple class refractory, penta-exposed multiple myeloma (MM) patients treated with selinexor plus dexamethasone or conventional care: a combined analysis of … LJ Costa, P Hari, SK Kumar, S Tang, UH Gandhi, JJ Shah, S Jagannath, ... Blood 134, 3125, 2019 | 13 | 2019 |
| Subsequent treatment outcomes of multiple myeloma refractory to CD38-monoclonal antibody therapy RF Cornell, UH Gandhi, A Lakshman, Z Gahvari, MH Jagosky, ... Blood 132, 2015, 2018 | 12 | 2018 |
| Mode of progression in smoldering multiple myeloma: a study of 406 patients NH Abdallah, A Lakshman, SK Kumar, J Cook, M Binder, P Kapoor, ... Blood cancer journal 14 (1), 9, 2024 | 10 | 2024 |
| Natural history of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody-based treatment UH Gandhi, A Lakshman, Z Gahvari, E McGehee, MH Jagosky, R Gupta, ... Blood 132, 3233, 2018 | 9 | 2018 |
francis buadi在 mayo.edu 的电子邮件经过验证
